From all the above mentioned and in continuation to our efforts in exploring new candidates against HCC and as VEGFR-2 inhibitors43, herein we designed and synthesized a novel series of thiazoloquinoxaline derivatives coupled with sulfonamide moieties following the four pharmacophoric features required for occupying VEGFR-2 active binding site44. This evidence concerns the gene KDR and hepatocellular carcinoma.